Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share.

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...

Pfizer’s Nurtec (also received top honors in the 2023 report) AstraZeneca’s Breztri Exeltis’ Slynd Incyte’s Opzelura ...

The Justice Department changed its policy on foreign corruption cases, which might have put an end to investigations into the pharmaceutical company.

Shares of Pfizer offer a yield above 7% at recent prices. Pfizer is a pharmaceutical giant that has raised its dividend every year since 2009. Loss of patent-protected exclusivity for several ...

Bispecific antibodies are already available for treating multiple myeloma. FDA approval of Regeneron Pharmaceuticals’ new drug, Lynozyfic, comes with dosing flexibility that sets it apart from ...

Regeneron scores EU nod for bispecific antibody Lynozyfic, setting up clash with J&J and Pfizer For T-cell engagers, the immune side effect cytokine release syndrome is a known problem.